Redcare Pharmacy stock gains 4.77 percent as guidance rises

Published on 09/30/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock trades after the company lifted German Rx revenue guidance to EUR 730 million to EUR 760 million for 2026. Total revenue growth is now guided at 16 percent to 18 percent, with Q3 figures due October 29, 2026.

Automatisiertes Apotheken-Lager mit Robotersystem und unbeschrifteten Medikamentenboxen — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt automatisiertes Apotheken-Lager mit Roboter-Regalsystem und markenfreien Medikamentenschachteln, Illustration mit AI erstellt.

Redcare Pharmacy (NL0012044747) stock was trading at EUR 74.75 at Lang & Schwarz on September 30, 2026 at 4:08 p.m. CEST, up 4.77 percent versus the prior close of EUR 71.35. The move followed a second upgrade to fiscal 2026 guidance, with FT.com reporting the company announcement dated September 28, 2026.

Rx revenue drives the upgrade

Redcare now expects German prescription revenue of EUR 730 million to EUR 760 million in fiscal 2026, compared with its previous range of EUR 680 million to EUR 720 million. Total revenue growth guidance also moved from 15 percent to 17 percent to 16 percent to 18 percent, while the adjusted EBITDA margin outlook stayed at 2.5 percent to 3.0 percent, according to FT.com.

Preliminary German Rx revenue grew 56 percent year over year in the third quarter and 51 percent in September. The company attributed the upgrade to continued momentum in e-prescriptions, while non-Rx growth guidance remained at 10 percent to 12 percent.

Profitability remains the test

The second-quarter figures show why revenue growth is not the only issue. Stockhouse reported that Q2 2026 group revenue rose 20 percent to EUR 853 million, while adjusted EBITDA increased 63 percent to EUR 29.60 million and the adjusted EBITDA margin expanded from 2.60 percent to 3.50 percent.

The same report noted that gross margin declined from 23.80 percent to 22.10 percent as prescription products took a larger share of sales. That contrast gives the guidance update its central investment question: whether fast German Rx growth can scale without diluting profitability.

Jefferies keeps EUR 97.00 target

On September 3, 2026, Jefferies maintained its Buy rating and EUR 97.00 price target, while noting weaker August active-customer and app-use trends. The assessment was published by finanzen.net.

Redcare stock trades above EUR 74

Redcare Pharmacy stock was trading at EUR 74.75 at Lang & Schwarz on September 30, 2026 at 4:08 p.m. CEST, up 4.77 percent versus the Lang & Schwarz prior close of EUR 71.35. The company is scheduled to publish its Q3 2026 interim statement on October 29, 2026, according to FT.com.